Administer SubQ; do not inject IV. Vial: Reconstitute with 1.5 to 5 mL diluent provided. An increased risk of second neoplasm has been reported in childhood cancer survivors treated with somatropin; the most common second neoplasms were meningiomas in patients treated with radiation to the head for their first neoplasm. Adjustment of antidiabetic medications may be necessary.• Hypersensitivity: Serious systemic hypersensitivity reactions, including anaphylactic reactions and angioedema, have been reported.• Intracranial hypertension: Intracranial hypertension with headache, nausea, papilledema, visual changes, and/or vomiting has been reported; symptoms usually occur within the first 8 weeks of therapy and signs and symptoms of intracranial hypertension may rapidly resolve after discontinuation or reduction of dose. The effect of hypopituitarism on life expectancy.
Before and after reconstitution, store at 2°C to 8°C (36°F to 46°F); do not freeze.
Store in original carton to protect from light; do not freeze.
If sensitivity to the diluent occurs or for use in newborns, reconstitute with SWFI.10 mg vial: Reconstitute with 1 mL of provided diluent. Use the 25-gauge mixing needle provided. Talk with the doctor.• High blood sugar like confusion, fatigue, increased thirst, increased hunger, passing a lot of urine, flushing, fast breathing, or breath that smells like fruit• Pancreatitis like severe abdominal pain, severe back pain, severe nausea, or vomiting• Adrenal gland problems like severe nausea, vomiting, severe dizziness, passing out, muscle weakness, severe fatigue, mood changes, lack of appetite, or weight loss• Low thyroid level like constipation; trouble handling heat or cold; memory problems; mood changes; or burning, numbness, or tingling feeling• Urinary tract infection like blood in the urine, burning or painful urination, passing a lot of urine, fever, lower abdominal pain, or pelvic pain• Severe cerebrovascular disease like change in strength on one side is greater than the other, trouble speaking or thinking, change in balance, or vision changes• Burning, numbness, pain, or tingling of hands, arms, legs, or feet• Increased intracranial pressure like vision changes, severe headache, nausea, or vomiting.• Signs of a significant reaction like wheezing; chest tightness; fever; itching; bad cough; blue skin color; seizures; or swelling of face, lips, tongue, or throat.Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.The easiest way to lookup drug information, identify pills, check interactions and set up your own personal medication records.
Acromegaly patients talk about snoring and sleep apnea "I had a dream…there were three compartments, this one I was in (gestures to the left), the one in the middle had no air in it and the one on the other side (gestures to the right) was alright…I had to get through the middle…and I got into the middle one and I couldn’t find my way out" The injection device should be clearly labeled with individual patient information to ensure that the correct pen is used (CDC 2012).Chronic kidney disease: Progression of renal osteodystrophy.Idiopathic short stature: Height, weight, pubertal development and adverse events every 3 to 6 months (Cohen 2008).Prader-Willi syndrome: Signs of upper airway obstruction (including onset of or increased snoring), sleep apnea, respiratory infections; effective weight control.Turner syndrome: Ear disorders including otitis media; cardiovascular disorders (eg, stroke, aortic aneurysm/dissection, hypertension).Noonan syndrome: Prior to use, verify short stature syndrome.Adequate somatropin use prior to conception may improve fertility in women with hypopituitarism (Vila 2019).During normal pregnancy, maternal production of endogenous growth hormone decreases as placental growth hormone production increases. Discard unused portion.Cartridge: Protect from light during storage. J Clin Endocrinol Metab. Treatment should be discontinued in patients who develop papilledema; resuming treatment at a lower dose may be considered once IH-associated signs and symptoms have resolved. Consult drug interactions database for more detailed information.• Elderly: Elderly patients may be more sensitive to the actions of somatropin; consider lower starting doses and smaller dose increments.• HIV patients: Patients with HIV infection should be maintained on antiretroviral therapy to prevent the potential increase in viral replication.• Pediatric: Failure to increase growth rate, particularly during the first year of therapy, indicates need for close assessment of compliance and evaluation for other causes of growth failure, such as hypothyroidism, undernutrition, advanced bone age, and antibodies to recombinant human GH.• Renal transplant recipients: No studies have been completed evaluating Nutropin or Nutropin AQ in patients with renal transplant. The nurse is reviewing the laboratory test results for a client admitted with a possible pituitary disorder. We comply with the HONcode standard for trustworthy health information - Hypoglycemia, or low blood sugar, may be detected easily from its physical and mental manifestations and measured using a blood test. Bates AS, Van't Hoff W, Jones PJ, Clayton RN.
Following reconstitution with sterile water for injection, use immediately and discard unused portion. If reconstituted with sterile water for injection, solution should be used immediately.Antidiabetic Agents: Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents. Protect from light.Cartridge: Store at 2°C to 8°C (36°F to 46°F); do not freeze. Pens in use may be stored in refrigerator and used within 4 weeks after initial injection or may be stored up to 3 weeks at ≤25°C (77°F).
If sensitivity to the diluent occurs or for use in newborns, reconstitute with sterile water for injection.Nutropin AQ: Allow device to come to room temperature and gently swirl; if solution is cloudy, do not use.Omnitrope vial: Reconstitute with provided diluent. PredniSONE: Somatropin may diminish the therapeutic effect of PredniSONE.